By Colin Kellaher
Eli Lilly & Co. (LLY) and Innovent Biologics Monday said a phase 3 study in China of Tyvyt in combination with Alimta and platinum met its primary endpoint of progression-free survival in a form of lung cancer.
The companies said the combination showed a statistically significant improvement in progression-free survival compared with placebo in first-line advanced or recurrent nonsquamous non-small cell lung cancer, without sensitive EGFR mutation or ALK rearrangement.
The safety profile of Tyvyt, which Innovent and Eli Lilly are jointly developing in China, was consistent with previous studies, and no new safety signals were identified, the companies said.
Eli Lilly and Innovent said they plan to initiate talks for registration with China's National Medical Products Administration in the near future.
Write to Colin Kellaher at firstname.lastname@example.org